• News
  • SAN DIEGO
  • BioTech

Neurocrine nets $9.5 million in 4Q

Neurocrine Biosciences Inc. (Nasdaq: NBIX) Friday announced its net income for the fourth quarter of 2012 rose to $9.5 million or $0.14 per fully diluted share, compared to net income of $1.3 million, or $0.02 per fully diluted share, for the same period in 2011.

For the year ended Dec. 31, 2012, the Neurocrine reported net income of $5 million, or $0.08 per fully diluted share, as compared to net income of $37.6 million, or $0.67 per fully diluted share, for 2011. One-time milestone payments of $30 million during 2011 were primarily responsible for the change in operating results year over year.

The company's balance sheet at Dec. 31, 2012, reflected total assets of $196 million, including cash, investments and receivables of $188.3 million compared with balances at Dec. 31, 2011 of $138.4 million and $131.7 million, respectively.

During January 2012, the Neurocrine completed a public offering of approximately 10.9 million shares of common stock that resulted in net proceeds of approximately $83 million.

RELATED ARTICLES:

Shire initiates Phase 3 study for patients with rare skin disorders

Bill Walton promotes NuVasive's spinal surgery around country

First patient treated in Genelux's Phase 1 trial

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

User Response
0 UserComments

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

Neurocrine Biosciences Inc.

Company Website

12790 El Camino Real
San Diego, CA 92130

Company Trade Data

Stock Symbol Close
Change
Chg %Chg
Volume
52-Week
High Low
NBIX
47.93
  -0.63  
- 1.30%
1,136,515,000
56.97
16.15

Insider Trade Data

Date Insider Shares Type Value
10/16/2015 Bozigian, Haig P 25,000 Sell $1,194,500
10/16/2015 Coughlin, Timothy P 25,000 Sell $1,194,500
10/16/2015 Gano, Kyle 25,000 Sell $1,194,250
10/16/2015 Gorman, Kevin Charles 33,500 Sell $1,600,295
10/16/2015 Grigoriadis, Dimitri E 25,000 Sell $1,194,250

Neurocrine Biosciences Inc. Executive(s):

Kevin Gorman

  • Chief Executive Officer, President

Similar Companies

NAICS - 541711 - Research and Development in Biotechnology
Subscribe Today!